A randomized study of two dose levels of intravenous (IV) clofarabibe (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Jabbour, E. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Kashani, F. Ravandi [1 ]
Borthakur, G. [1 ]
Estrov, Z. [1 ]
Gandhi, V. [1 ]
Byrd, A. [1 ]
Kwari, M. [1 ]
Faderi, S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6504
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Gandhi, Varsha
    Byrd, Anna L.
    Kwari, Monica
    Cortes, Jorge
    Kantarjian, Hagop M.
    [J]. CANCER, 2012, 118 (03) : 722 - 728
  • [2] A RANDOMIZED STUDY OF DECITABINE ALTERNATING WITH CLOFARABINE VERSUS DECITABINE ALONE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Faderl, S.
    Garcia-Manero, G.
    Kadia, T.
    Borthakur, G.
    Jabbour, E.
    Ravandi, F.
    Estrov, Z.
    Cortes, J.
    Autry, J.
    Kantarjian, H.
    [J]. HAEMATOLOGICA, 2012, 97 : 369 - 369
  • [3] Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS)
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Thomas, Deborah A.
    Gandhi, Varsha
    Plunkett, William
    Byrd, Anna
    Kwari, Monica
    Kantarjian, Hagop M.
    [J]. BLOOD, 2008, 112 (11) : 89 - 89
  • [4] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    [J]. BLOOD, 2008, 112 (11) : 91 - 91
  • [5] Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge E.
    O'Brien, Susan
    Gandhi, Varsha
    Plunkett, William
    Byrd, Anna
    Kwari, Monica
    Kantarjian, Hagop M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2755 - 2760
  • [6] Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge
    O'Brien, Susan
    Gandhi, Varsha
    Plunkett, William
    Byrd, Anna L.
    Kwari, Monica
    Kantarjian, Hagop
    [J]. BLOOD, 2009, 114 (22) : 53 - 54
  • [7] Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA)
    Komrokji, Rami S.
    Donoso, Leyla Hernandez
    Hodzic, Sejla
    Owusu, Henry F.
    Nolan, Kevin
    Nourry, Claire
    Diez-Campelo, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [9] PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)
    Mufti, G. J.
    Garcia-Manero, G.
    Hovarth, N.
    Lim, Z.
    Quesnel, B.
    Leone, G.
    Bennett, J.
    Sanz, G.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 369 - 370
  • [10] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
    Chen, James Yuhtyng
    Johnson, Lisa
    McKenna, Kelly Marie
    Choi, Timothy S.
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan M.
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris H. M.
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345